By Fineline Cube 
German pharmaceutical giant Merck KGaA (ETR: MRK) has completed its USD 3.4 billion (EUR 3 billion) acquisition of US-based SpringWorks Therapeutics, marking one of the largest M&A deals in the global biopharmaceutical sector in 2025. This transaction, initially announced in April, is set to drive Merck’s revenue growth and enhance its diluted earnings per share (pre-EPS) by 2027.
SpringWorks’ Innovative Therapies
SpringWorks brings two innovative rare oncology therapies to Merck’s portfolio. Ogsiveo (nirogacestat), the first FDA-approved oral gamma-secretase inhibitor for treating adult desmoid tumors, and Gomekli (mirdametinib), an oral small-molecule MEK inhibitor approved by the FDA for pediatric and adult patients with neurofibromatosis type 1 (NF1) with symptomatic plexiform neurofibromas (PN) that cannot be completely resected. Both therapies received positive CHMP opinions from the European Medicines Agency (EMA) in May and June 2025.
Strengthening Merck’s Rare Oncology Pipeline
This acquisition strengthens Merck’s rare oncology pipeline, which already includes pimicotinib, a tenosynovial giant cell tumour (TGCT) treatment co-developed by China’s Abbisko Therapeutics that has been filed for marketing in China.-Fineline Info & Tech